Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) With Erlotinib (OSI-774): Early Termination Due to Increased Toxicities
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-0746
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2004
Authors
Publisher
American Association for Cancer Research (AACR)